S
Seres Therapeutics Inc (MCRB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$1.41
+0.01 (+0.71%)
Market Cap: $14.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Seres Therapeutics Inc (MCRB) Valuation Multiples
Seres Therapeutics (MCRB) trades at 6.6x sales and 0.7x book value. Its P/S of 6.6x is below its 10-year median of 13.0x. Its forward P/E is 10.8x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 10.8x |
| Price to sales | 6.6x |
| Price to book | 0.7x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 6.6x | N/A | 13.0x |
Valuation History
Over the 8 of the 10 year ends shown that have a P/S, its P/S ranged from 5.2x in 2019 to 670.5x in 2022.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $14.88 | N/A | 3.0x |
| 2024 | $16.62 | N/A | 5.3x |
| 2023 | $28.00 | 119.1x | N/A |
| 2022 | $112.00 | 670.5x | 65.0x |
| 2021 | $166.60 | 5.3x | 5.8x |
| 2020 | $490.00 | 82.4x | 12.8x |
| 2019 | $69.00 | 5.2x | N/A |
| 2018 | $90.40 | 6.5x | N/A |
| 2017 | $202.80 | 12.8x | 6.8x |
| 2016 | $198.00 | 18.2x | 3.0x |
Frequently Asked Questions About MCRB
What is MCRB's forward P/E ratio?
Seres Therapeutics has a forward P/E ratio of 10.8x.
What is MCRB's price to sales ratio?
Seres Therapeutics has a price to sales ratio of 6.6x.
MCRB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors